Clinical Trials Logo

Hepatitis C clinical trials

View clinical trials related to Hepatitis C.

Filter by:

NCT ID: NCT05071261 Not yet recruiting - Clinical trials for Hepatitis C Virus Infection

Screening, Treatment, and Eradication of Hep C

Start date: April 1, 2024
Phase:
Study type: Observational

The aim of this study is to assess the HCV screening rate in Arizona by identification of potential HCV patients/subjects through different methods of communication - text message, email, social media, radio, newspaper ads, and flyers.

NCT ID: NCT04690972 Not yet recruiting - Liver Cancer Clinical Trials

"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".

LivMOD
Start date: December 20, 2020
Phase:
Study type: Observational

Development of preclinical translational models for chronic liver tumors and diseases study, such as spheroids cultured in autologous medium and murine xenograft models to test the efficacy of new therapeutic strategies.

NCT ID: NCT04618679 Not yet recruiting - Hepatitis C Clinical Trials

Application of 18F-FDOPA PET in Research of the Association Between HCV Infection and Parkinson's Disease.

Start date: November 2, 2020
Phase:
Study type: Observational

-[18F]Fluoro-L-3,4-dihydroxyphenylalanine (18F-FDOPA) positron emission tomography (PET) is a imaging marker for presynaptic dopaminergic neuronal function. The decreased uptake of 18F-FDOPA in the posterior putamen is demonstrated in the early course of PD, and could differentiate early PD from healthy controls. The objective of this study is to investigate the evidence of presynaptic dopaminergic neuronal dysfunction in the preclinical stage of PD, which may be associated with HCV infection.

NCT ID: NCT04543643 Not yet recruiting - Clinical trials for Gastroesophageal Varices

Endoscopic and Microbiological Assessment of the Effect of Carvedilol Combined With Berberine on GOV in Cirrhosis

CABER
Start date: November 1, 2021
Phase: Phase 3
Study type: Interventional

Carvedilol has been shown to be more potent in decreasing portal hypertension to propranolol. A lot of studies have shown that the imbalance of flora and the progress of portal hypertension are mutually causal. Berberine can regulate the intestinal flora.In this study, we evaluated the effect of carvedilol and berberine on reducing portal vein pressure by observing the changes of endoscopy,endoscopic ultrasonography and intestinal flora.

NCT ID: NCT04470271 Not yet recruiting - Viral Hepatitis C Clinical Trials

Re-linkage to Care of Patients With Hepatitis C

Start date: September 1, 2020
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to identify patients with chronic hepatitis C virus (HCV) who were lost of follow up and relinkage them to hepatitis C care

NCT ID: NCT04428346 Not yet recruiting - Clinical trials for Hepatitis C, Chronic

A Trial to Assess the Effect of an Intervention Integrating Contingency Management (Financial Incentives) to Enhance Hepatitis C Treatment Uptake Following Dried Blood Spot Hepatitis C RNA Testing Among People With Recent Injecting Drug Use Attending Needle and Syringe Programs

AMPLIFY
Start date: October 2022
Phase: N/A
Study type: Interventional

A pilot two-arm, individual-level, randomised controlled trial to assess the effect of an intervention integrating contingency management (financial incentives) to enhance hepatitis C treatment uptake following dried blood spot hepatitis C RNA testing among people with recent injecting drug use attending needle and syringe programs: the AMPLIFY study

NCT ID: NCT04244383 Not yet recruiting - Hepatitis C Clinical Trials

Expression of Inflammasomes in HCV Patients

Inflammasome
Start date: January 2020
Phase: Phase 4
Study type: Interventional

Hepatitis C virus has been identified a quarter of a decade ago as a leading cause of chronic viral hepatitis that can lead to cirrhosis and hepatocellular carcinoma. Only a minority of patients can clear the virus spontaneously during acute infection. Elimination of HCV during acute infection correlates with a rapid induction of innate and a delayed induction of adaptive immune responses. The majority of patients is unable to clear the virus and develops viral persistence despite the ongoing innate and adaptive immune response. The virus usually develops several strategies to escape these immune responses.

NCT ID: NCT04220151 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Epigenetic Changes in Hepatocellular Carcinoma Developed After Direct Acting Antiviral Therapy for Chronic Hepatitis C

Start date: March 1, 2020
Phase:
Study type: Observational

Hepatocellular carcinoma (HCC) is the most common type of liver cancer, its survival rate ranks only second to lung cancer and it is a severe threat to human health. In Egypt, HCC constitutes a significant public health problem. Where it is responsible for 33.63% and 13.54% of all cancers in males and females respectively. It has a poor prognosis after discovery, which is usually at a late stage of disease. This had been strongly linked to the hepatitis C virus epidemic that affected around 10-15% of the Egyptian population during the last 3 decades, and was reported as the highest prevalence of HCV in the world. However, the pathophysiological mechanisms involved remain unclear. The occurrence of HCC is a complicated process involving multiple genes and steps. Imbalances in cellular signal transduction pathways, deficiencies in DNA repair regulating genes, activation of protooncogenes, inactivation of tumor suppressor genes and epigenetic modifications all promote the occurrence of liver cancer.

NCT ID: NCT04122066 Not yet recruiting - Hepatitis C Clinical Trials

the Pulmonary Safety of Antihepatitis C Treatment

Start date: June 2020
Phase:
Study type: Observational

pulmonary side effects of the new regimen of antihepatitis C

NCT ID: NCT03992313 Not yet recruiting - Hepatitis C Clinical Trials

Community Versus Facility-based Services to Improve the Screening of Active HCV Infection in Cambodia

Cam-C
Start date: August 1, 2019
Phase: N/A
Study type: Interventional

The Principal objective is to compare the effectiveness of a community-based intervention to a facility-based intervention to improve the combined-testing uptake (Antibody + RNA) of HCV infection among general population aged more than 40 years old in Cambodia Secondary objectives : - To compare the HCV antibody testing uptake between the 2 arms for the eligible population - To compare the active case detection rate between the 2 arms for the eligible population - To compare the linkage to care between the 2 arms for those with active infection - To compare the cost-effectiveness of the two strategies